From the Journals

Personalizing Steroid Duration in Asthma

Researchers tested whether a readily available biomarker can individualize systemic corticosteroid prescribing during asthma-related hospitalizations.

Share

  • 1

    Study evaluates eosinophil count-guided corticosteroid duration for asthma.

  • 2

    Conducted in Singapore with 110 adult patients.

  • 3

    Eosinophil-guided approach reduced steroid exposure.

  • 4

    Treatment failure rate: 11% (eosinophil-guided) vs 7% (usual care).

  • 5

    60% patients had eosinophilic exacerbations.

  • 6

    No severe complications observed in either group.

  • 7

    Requires larger, diverse studies for confirmation.

  • 8

    Findings published in Thorax by Anthony Yii and colleagues.

Original Source(s)

Personalizing Steroid Duration in Asthma

Researchers tested whether a readily available biomarker can individualize systemic corticosteroid prescribing during asthma-related hospitalizations.

  • by Kathryn Wighton

  • February 3, 2026

  • 3 min

Related Content

A Persistent Cough and an Unexplained Diagnosis

NEJM case details the diagnostic evaluation of an 80-year-old woman with weeks of respiratory symptoms, weight loss, and diffuse ground-glass opacities on chest CT.

New Vaccine Prevents Severe RSV Illness

A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

Mepolizumab Reduces COPD Flares in Eosinophilic Patients

A new clinical trial found that adding mepolizumab to standard inhaled therapy significantly reduced moderate or severe COPD exacerbations in patients with high eosinophil counts, with a 21% lower annual rate and longer time to first flare.